Tyra Biosciences Inc (NAS:TYRA)

$ 14.09 -0.16 (-1.12%) Market Cap: 713.00 Mil Enterprise Value: 359.18 Mil PE Ratio: 0 PB Ratio: 2.06 GF Score: 40/100

Tyra Biosciences Inc at TD Cowen Oncology Innovation Summit (Virtual) Transcript
May 30, 2023
Tyra Biosciences Inc at Bank of America Global Healthcare Conference Transcript
May 11, 2023
Tyra Biosciences Inc To Discuss Expansion of TYRA-300 Development Call Transcript
Mar 01, 2023
Tyra Biosciences Inc To Discuss 300 First Patient Dosed Call Transcript
Nov 29, 2022

Tyra Biosciences Inc To Discuss 300 First Patient Dosed Call Transcript

Nov 29, 2022 / 02:00PM GMT

Release Date Price: $6.77 (+4.80%)

Transcript

Operator

Good day, ladies and gentlemen, and thank you for standing by. Welcome to the Tyra Biosciences' conference call to discuss the first patient dosed with TYRA-300 and the SURF301 study. As a reminder, this conference is being recorded.

Now I'd like to turn the conference call over to Amy Conrad from Investor Relations. Please proceed.

Amy Conrad

Thank you, Jamie. Good morning, everyone, and thank you for joining us. With me today from Tyra are Todd Harris, Chief Executive Officer; and Hiroomi Tada, our Chief Medical Officer. Also on today's call is Dr. Jonathan Rosenberg, Chief of the Genitourinary Medical Oncology Service, Division of Solid Tumor Oncology and the Enno W. Ercklentz Chair of Memorial Sloan Kettering Cancer Center.

For those of you participating via conference call, the slides are made available via webcast and can also be accessed by going to the Investor Relations page of our website following conclusion of today's call.

Todd will provide introductory remarks and will review the outsized market opportunity for TYRA-300 and

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.